MX2022000474A - Camptothecin derivatives with a disulfide moiety and a piperazine moiety. - Google Patents

Camptothecin derivatives with a disulfide moiety and a piperazine moiety.

Info

Publication number
MX2022000474A
MX2022000474A MX2022000474A MX2022000474A MX2022000474A MX 2022000474 A MX2022000474 A MX 2022000474A MX 2022000474 A MX2022000474 A MX 2022000474A MX 2022000474 A MX2022000474 A MX 2022000474A MX 2022000474 A MX2022000474 A MX 2022000474A
Authority
MX
Mexico
Prior art keywords
moiety
compounds
piperazine
camptothecin derivatives
disulfide
Prior art date
Application number
MX2022000474A
Other languages
Spanish (es)
Inventor
Jiten Ranchhodbhai Patel
Gopalkumar Chimanlal Patel
Trinadha Rao Chitturi
Prabal Sengupta
Omkar Prakash Gore
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2022000474A publication Critical patent/MX2022000474A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof (wherein X, Y, Z and n are defined herein). These compounds are useful in the treatment of diseases mediated by topoisomerase I enzyme such as cancers. The present invention also provides processes for the preparation of compounds of Formula I. The compounds of the present invention are more water soluble, stable in buffer solution at various pH, and exhibit better anti-tumor activity and rapid release of SN-38 in tumor microenvironments.
MX2022000474A 2019-07-11 2020-07-13 Camptothecin derivatives with a disulfide moiety and a piperazine moiety. MX2022000474A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921027783 2019-07-11
PCT/IB2020/056580 WO2021005583A1 (en) 2019-07-11 2020-07-13 Camptothecin derivatives with a disulfide moiety and a piperazine moiety

Publications (1)

Publication Number Publication Date
MX2022000474A true MX2022000474A (en) 2022-03-11

Family

ID=71670329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000474A MX2022000474A (en) 2019-07-11 2020-07-13 Camptothecin derivatives with a disulfide moiety and a piperazine moiety.

Country Status (11)

Country Link
US (1) US20220242874A1 (en)
EP (1) EP3997094A1 (en)
CN (1) CN114341141A (en)
AU (1) AU2020309244A1 (en)
BR (1) BR112022000401A2 (en)
CA (1) CA3146510A1 (en)
CL (1) CL2022000045A1 (en)
IL (1) IL289677A (en)
MX (1) MX2022000474A (en)
PE (1) PE20221005A1 (en)
WO (1) WO2021005583A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022153211A1 (en) * 2021-01-13 2022-07-21 Sun Pharma Advanced Research Company Limited Liposomal composition of a camptothecin derivative

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
WO2003043584A2 (en) 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins
ITRM20020306A1 (en) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti ESTERS IN POSITION 20 OF CAMPTOTECINE.
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN102448494B (en) 2009-02-13 2016-02-03 免疫医疗公司 There is the immune conjugates of the key of cleavable in born of the same parents
WO2012067670A1 (en) 2010-11-18 2012-05-24 Saladax Biomedical Inc. Irinotecan immunoassay
CN102850400A (en) 2011-06-30 2013-01-02 周文强 Camptothecin derivative, and preparation method, pharmaceutical composition and use thereof
CN102516258B (en) 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 Water-soluble vitamin E derivative modified fat-soluble anti-cancer drug compound and preparation, preparation method and application of compound
CN103508981A (en) 2012-06-18 2014-01-15 北京美倍他药物研究有限公司 New piperazine derivative and medical applications
KR20140010517A (en) 2012-07-12 2014-01-27 고려대학교 산학협력단 Drug delivery complex enabling direct monitoring of delivery and cellular uptake of the drug and method for preparing the same
US9150585B2 (en) 2012-11-13 2015-10-06 Fl Therapeutics Llc Analogs of camptothecin
US10098967B2 (en) 2012-12-03 2018-10-16 Ohio State Innovation Foundation Self-assembly of therapeutic agent-peptide nanostructures
CN104370862B (en) 2013-08-13 2019-04-23 中国人民解放军军事医学科学院毒物药物研究所 Water-soluble antitumor compound
CN103524519B (en) 2013-09-24 2015-06-24 中国科学技术大学 Camptothecin prodrug monomer and polymeric prodrug amphipathic molecules thereof as well as preparation method and application of camptothecin prodrug monomer and polymeric prodrug amphipathic molecules
CN103552010A (en) 2013-11-07 2014-02-05 凡嘉科技（无锡）有限公司 Special slide dish forceps
WO2015178265A1 (en) 2014-05-23 2015-11-26 日本化薬株式会社 Novel glutamic acid derivative and use thereof
CN104306332B (en) 2014-09-24 2017-02-15 东南大学 Camptothecin phospholipid compound, and medicinal composition and application thereof
CN104368011B (en) 2014-11-27 2017-05-10 东南大学 Pharmaceutical betaine conjugate and pharmaceutical composition and application thereof
CN105131039B (en) 2015-09-18 2017-09-15 东南大学 A kind of camptothecin phosphatide cpd, its pharmaceutical composition and application
CN105457038A (en) 2015-11-09 2016-04-06 东南大学 Quick release type medicine phosphatide compound and medicine composition thereof
US20200078468A1 (en) * 2016-04-13 2020-03-12 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
WO2017210246A2 (en) * 2016-05-31 2017-12-07 Tarveda Therapeutics, Inc. Penicillamine conjugates and particles and formulations thereof
CN106046029B (en) 2016-06-01 2019-01-22 西南大学 A kind of reproducibility response amphipathic small molecules prodrug and preparation method thereof
CN106620717B (en) 2016-12-13 2020-11-24 上海交通大学 Amphiphilic conjugate anti-tumor nano-drug with function of reversing tumor multi-drug resistance and preparation method and application thereof
CN106967081A (en) 2017-03-17 2017-07-21 南开大学 A kind of synthetic method of the integrated medicine of the diagnosis and treatment with Chemosensitizing effect
CN106946899B (en) 2017-03-21 2018-11-23 莎穆(上海)生物科技有限公司 A kind of camptothecin prodrug and its preparation and application
CN106916236B (en) 2017-03-27 2019-04-09 莎穆(上海)生物科技有限公司 A kind of cyclodextrin-camptothecin supermolecule chemotherapeutics and its preparation and application
CN108785683A (en) 2017-04-27 2018-11-13 西南大学 A kind of preparation method of reduction response medicine-drug conjugates
CN108409756B (en) 2018-03-08 2019-12-10 莎穆(上海)生物科技有限公司 Camptothecin-based heterodimer multifunctional prodrug and preparation method and application thereof
CN108586535A (en) 2018-07-03 2018-09-28 哈尔滨理工大学 Phospholipid analogues, the Preparation method and use of the structure containing camptothecine

Also Published As

Publication number Publication date
AU2020309244A1 (en) 2022-03-03
CN114341141A (en) 2022-04-12
CA3146510A1 (en) 2021-01-14
EP3997094A1 (en) 2022-05-18
CL2022000045A1 (en) 2022-11-04
BR112022000401A2 (en) 2022-03-29
PE20221005A1 (en) 2022-06-15
IL289677A (en) 2022-03-01
WO2021005583A1 (en) 2021-01-14
US20220242874A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
MX2023010806A (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones.
NZ766835A (en) Pharmaceutical compounds
MX2020001235A (en) 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs.
GEP20227433B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
MX2022001908A (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors.
WO2018141002A3 (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
JP2018507197A5 (en)
PE20090506A1 (en) DERIVATIVES OF IMIDAZO- [1,2-b] -PYRIDAZINE AS INHIBITORS OF ALK5 AND / OR ALK4
BRPI0409198A (en) quinolin-2-one derivatives for the treatment of airway diseases
WO2005105753A3 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
TN2018000078A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
EA200800516A1 (en) DERIVATIVES N-PHENYL-2-PYRIMIDINAMINE AND THE PROCESS OF THEIR RECEPTION
MX2012001420A (en) Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors.
MX2008012422A (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors.
EA201000090A1 (en) Triple substituted derivatives of pyrimidine for the treatment of proliferative diseases
JP2019519512A5 (en)
CY1108246T1 (en) 1H-SULIUM PRODUCT [2,3-c] PYRAZOLIS USEFUL AS MOBILE INHIBITORS
MX2022013657A (en) Heteroaromatic macrocyclic ether chemotherapeutic agents.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2022002219A (en) Triazolopyrimidines as a2a / a2b inhibitors.
CR20220018A (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits
WO2004060264A3 (en) Metastin derivatives and their use
PE20070167A1 (en) COMPOUNDS 5H-BENZO [4,5] CYCLOHEPTA [1,2-b] PYRIDINE AS INHIBITORS OF TYROSINE KINASE
MX2023004937A (en) Solid state forms of substituted pyrazolopyrimidines and uses thereof.
JOP20210083A1 (en) Antibody drug conjugates comprising ecteinascidin derivatives